Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05852431 · ClinicalTrials.gov registry record · Phase 3

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

A Phase 3 study of Severe Hypertriglyceridemia, sponsored by 89bio.

Active
Registry status
Phase 3
Development phase
360
Enrollment target
20
Study locations

NCT05852431: Active Phase 3 study of Severe Hypertriglyceridemia, sponsored by 89bio.

NCT05852431 is a Phase 3 study of Severe Hypertriglyceridemia that is active but no longer recruiting, run by 89bio. The registered enrollment target is 360 participants, roughly in line with the 380-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target. The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05852431, a Phase 3 study of Severe Hypertriglyceridemia, is active but no longer recruiting, sponsored by 89bio.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
360 participants
Enrollment target
20
Study locations

Study Summary

To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.

Interventions

  • DRUG Placebo
  • DRUG Pegozafermin

Study Locations (20)

California

  • 89bio Clinical Trial Site - Huntington Park
  • 89Bio Clinical Study Site - Long Beach
  • 89bio Clinical Study Site - Los Angeles
  • 89bio Clinical Trial Site - Northridge
  • 89bio Clinical Trial Site - Panorama City
  • 89bio Clinical Study Site - Santa Ana
  • 89bio Clinical Trial Site - Santa Ana
  • 89bio Clinical Study Site - Thousand Oaks
  • 89Bio Clinical Study Site - Tustin

Arizona

  • 89bio Clinical Study Site - Chandler
  • 89bio Clinical Study Site - Peoria
  • 89Bio Clinical Study Site - Tucson

Arkansas

  • 89bio Clinical Study Site - Conway
  • 89bio Clinical Study Site - Jonesboro
  • 89bio Clinical Study Site - Little Rock

Colorado

  • 89bio Clinical Study Site - Wheat Ridge
  • 89bio Clinical Trial Site - Wheat Ridge

Florida

  • 89Bio Clinical Study Site - Clearwater
  • 89bio Clinical Study Site - Clearwater

Connecticut

  • 89bio Clinical Study Site - Bridgeport

Trial Details

FieldValue
Enrollment Target 360 participants
Start Date 2023-06-15
Est. Completion 2026-04
Phase Phase 3
89bio

7 total trials

What the registry record for NCT05852431 still lists

NCT05852431 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 380-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target.

The record links to 1 condition, with Severe Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05852431 names 20 study sites across 6 states, led by California, Arizona, Arkansas.

Frequently Asked Questions

What is clinical trial NCT05852431 about?

NCT05852431 is a clinical study titled "To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia". To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.

What is the current status of trial NCT05852431?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2023-06-15. Estimated completion is 2026-04.

What conditions does trial NCT05852431 study?

This clinical trial studies the following conditions: Severe Hypertriglyceridemia.

What interventions are being tested in trial NCT05852431?

The interventions under investigation include: Placebo (DRUG), Pegozafermin (DRUG).

Who is sponsoring clinical trial NCT05852431?

This trial is sponsored by 89bio, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05852431 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Severe Hypertriglyceridemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05852431's enrollment target sits among peer trials

360 5th of 8 higher than 4 of 8 other Severe Hypertriglyceridemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Severe Hypertriglyceridemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02747836 · 360 participants

    Ultrasound Analysis of Human Carpal Tunnel System

  • NCT04089046 · 360 participants · NA

    Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)

  • NCT04130503 · 360 participants · NA

    The Recovery in Stroke Using PAP Study

  • NCT04160000 · 360 participants · Phase 4

    Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05852431, the US trial registry maintained by the National Library of Medicine. NCT05852431 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.